Non-Small-Cell Lung Cancer | Landscape & Forecast | Disease Landscape & Forecast

Publish date: May 2019

Login to access report

Market Outlook

Non-small-cell lung cancer (NSCLC) is one of the most dynamic oncology indications and a key area of focus for drug developers. Immune checkpoint inhibitors have transformed the management of advanced NSCLC. In late 2018, Tecentriq (Roche/Genentech/Chugai) was the second immune checkpoint inhibitor to enter the coveted first-line metastatic setting, after Keytruda (Merck & Co.). Competition is set to intensify further over the forecast period as multiple combination therapies based on immune checkpoint inhibitors gain approval and enter the clinic. In addition, novel biomarker-driven therapies such as next-generation EGFR and ALK inhibitors are vying for a share of the increasingly crowded and competitive NSCLC market.

Questions Answered

  •  How large are the drug-treatable NSCLC populations and how will drug-treatment rates change over time in market-relevant populations?
  • How will recent and expected market approvals shape uptake of immune checkpoint inhibitors in first-line metastatic NSCLC? Which agents and combinations will dominate this commercially lucrative disease setting?
  • What pipeline products are most promising, and what uptake and sales could they secure in NSCLC? What therapies of note are progressing in earlier phases of development?
  • What are the key market drivers and constraints in NSCLC, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • Key Updates
      • May 2019
      • December 2018
      • October 2018
      • September 2018
    • Market Outlook
      • Market Outlook
        • Market Overview
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for NSCLC?
        • What Factors Are Constraining the Market for NSCLC?
      • Segment-Specific Trends
        • Stage IB-II NSCLC
        • Stage III NSCLC
        • First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer
        • Second- and Third-Line Treatment of Metastatic Non-Small-Cell Lung Cancer
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Etiology and Pathophysiology
      • Etiology and Pathophysiology
        • Expert Insight
        • Disease Overview
        • Pathophysiology
        • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Diagnosed Incident Cases
        • Stage Distribution at Diagnosis
        • Recurrent Incident Cases
        • Drug-Treatable Populations
        • Drug-Treated Populations
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • EGFR Inhibitors
        • ALK Inhibitors
        • Immune Checkpoint Inhibitors
        • BRAF/MEK Inhibitors
        • Angiogenesis Inhibitors
        • Cytotoxic Agents
      • Medical Practice
        • Region-Specific Treatment Practices
    • Unmet Need
      • Introduction
        • Expert Insight
      • Attainment of Unmet Needs
        • Current Attainment of Unmet Needs in Non-Small-Cell Lung Cancer
        • Future Attainment of Unmet Needs
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for NSCLC
        • ALK Inhibitors
        • ROS1 Inhibitors
        • Immune Checkpoint Inhibitors
        • Angiogenesis Inhibitors
        • Poly ADP-Ribose Polymerase Inhibitors
        • Therapeutic Vaccines
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for NSCLC
    • Access and Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
      • U.S. Reimbursement Dynamics
        • Reimbursement Dynamics in Biomarker Targeted Metastatic NSCLC in the United States: Current and Future
      • EU5 Reimbursement Dynamics
        • Payer Insight on Future Reimbursement of Biomarker-Targeted Therapies for NSCLC
      • EU5 Access & Reimbursement Considerations for Emerging Therapies
        • Access & Reimbursement Considerations for Emerging Biomarker-Targeted NSCLC Therapies in the EU5
        • Payer Insight on Emerging Biomarker-Targeted NSCLC Therapies
      • China Reimbursement Dynamics: Current & Future
      • China Access & Reimbursement Considerations for Emerging Therapies
        • Payer Insight on Emerging Therapies for CRC
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug- and Regimen-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Cycles of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • NSCLC Bibliography

Author(s): Joshua Dawkins, M.Pharmacol., PhD; Khurram Nawaz, MSc

Joshua Dawkins, , is a Business Insights Analyst in the oncology team at Decision Resources Group. Prior to joining DRG, Dr. Dawkins obtained his doctorate in molecular biology at the Barts Cancer Institute, Queen Mary University of London, where he investigated the roles of epigenetic histone modifiers in pancreatic ductal adenocarcinoma. Dr. Dawkins also holds a Master of Pharmacology degree awarded by the University of Bath, and completed a one-year professional placement within the oncology team at MedImmune.

Khurram Nawaz is a director in the oncology team at Decision Resources Group. Mr. Nawaz manages a team of analysts who conduct extensive primary and secondary market research on several oncology indications across the major pharmaceutical markets. He also provides sales and client support on syndicated and custom oncology products, translating domain knowledge into actionable insights. Previously, Mr. Nawaz was a principal analyst in the oncology team at Decision Resources Group, where he developed considerable expertise in forecasting complex oncology and hemato-oncology drug markets, and conducted detailed primary research with physicians and payers across multiple geographies. He has in-depth expertise in immuno-oncology, non-small-cell lung cancer, prostate cancer, multiple myeloma, and other solid and hematological malignancies. Prior to joining Decision Resources Group, Mr. Nawaz was a scientist at GlaxoSmithKline, where he contributed to the development of candidate drugs for schizophrenia and cognitive disorders. He holds a in biotechnology from the École Supérieure d'Ingénieurs de Luminy (now Polytech Marseille), University of Aix-Marseille, and a in life sciences from the Pierre and Marie Curie–Paris VI University.